UAB Radiation Safety Procedure Manual, 9Th Edition, 2007

Total Page:16

File Type:pdf, Size:1020Kb

UAB Radiation Safety Procedure Manual, 9Th Edition, 2007 August 31, 2007 To Whom It May Concern: This manual was developed with the assistance of the Occupational Health and Safety staff, the Radioisotope & Radiation Safety Committee, and appropriate legal counsel and is published as the official policy of the University of Alabama at Birmingham for radiation studies and the activities surrounding those studies. Adherence to the procedures, practices, and recommendations described herein is essential if the University is to meet its obligation of providing a safe and healthful environment for study, training, and investigative pursuits. Many of our research and educational activities utilize ionizing radiation. Their success very much depends on the thoughtfulness and care exercised by every individual involved with the program. The UAB Department of Occupational Health and Safety is hereby charged with the responsibility of ensuring that the University of Alabama at Birmingham is in compliance with the provisions stated in this manual and other appropriate state, county, and federal radiation control regulations. All faculty, staff, employees, and students engaged in work involving radioactive materials or radiation- producing devices are expected to be familiar with and comply with the policies presented in this manual. Sincerely, Carol Z. Garrison President University of Alabama at Birmingham Radiation Safety Procedures Manual Ninth Edition 2007 2 TABLE OF CONTENTS I. Introduction....................................................................................... 5 II. ALARA – A Management Concept......................................................... 6 III. Radioisotope & Radiation Safety Committee................................ 7 IV. Radioactive Drug Research Committee......................................... 11 V. Subcommittee of Laboratory Use on Electronic Product Radiation........................................................................................... 14 VI. Radiation Safety Program................................................................ 21 VII. Responsibilities of Department Chairmen, Deans, and Administrators.................................................................................. 27 VIII. Responsibilities of Licensee.............................................................. 27 IX. Responsibilities of Individual User................................................... 30 X. Liability Aspects of Working with Radioactivity and Radiation Equipment.......................................................................... 31 XI. Instrument Calibration....................................................................... 32 XII. Surveys of Radioisotope and Radiation Use..................................... 32 XIII. Personnel Monitoring......................................................................... 36 XIV. Storage of Radioactive Material....................................................... 42 XV. Posting and Labeling......................................................................... 42 XVI. Procurement of Radioactive Materials.............. .............................. 43 XVII. Procedures for Working with Radioactive Material and Radiation Equipment................................................................... 45 XVIII. Use of Radionuclides in Experimental Animals.............................. 46 XIX. Emergency Procedures...................................................................... 47 XX. Transfer of Radioactive Material....................................................... 49 XXI. Disposal of Radioactive Material........................................................ 50 XXII. Sources of Concern.......................................................................... 52 3 APPENDICES A. UAB Radiation Safety Committees...................................................………….. 53 B. Criteria for Approval of Human Use Studies in Radioactive Drug Research................................................................………….. 55 C. Instructions for Operators of Particle Accelerators...................................... ..................................................…………. 57 D. Guide for External Radioisotope Monitoring....................................……….….. 58 E. Guide for Internal Radiochemical Monitoring..................................……….….. 61 F. Liquid Collection Technique to Minimize Spills and Contamination.............................................................................……….….. 77 G. Area Warning Signs, DOT Shipping Labels, and Radioactive Waste Tags............................................................……………. 78 H. Radioactive Waste Management.......................................................……………. 79 1. Radioactive Waste Minimization, A Mandatory Program (Supplement A).........................................................…………… 84 2. Methods Utilized by Licensee in A Radioactive Waste Minimization Program (Supplement B)... .............................…………… 85 I. Criteria for Approval of Radioisotope Licensure and Use.......................................................................................……….… 86 1. Nonhuman Use Criteria...............................................................…………… 86 2. Human Use Criteria.......................................................................………….. 87 3. Responsibilities & Supervision (Supplement A)………………………….… 89 4. Handling Techniques (Supplement B).......................................……………. 91 J. Criteria for Ventilation Design.......... ...............................................……………. 93 1. Criteria for Radiochemical Culture Work in Class II Type A Biosafety Cabinets (Supplement A)..........................................................................…………. 99 K. Radiation Dose Disclosure Form.........................................................………….. 101 L. Quarterly Report Form on Human Use Radioactive Drug Research............................................................................................………….... 103 M. Schedule of Deminimus Levels of Radioactivity... ........................…………….. 104 N. UAB Policy Regarding Radiation Exposure During Pregnancy ..…………….. 115 Pregnancy Precautions in Nuclear Medicine ………………………………….. 119 Pregnant Worker’s Guide ..............................................................…………… 120 Instructors Guide .............................................................................…………… 123 Effects of Risk Factors on Pregnancy Outcome...........................…………….. 125 Pregnancy Instruction Statement……………………………………………… 127 O. Radiation Safety Audit Schedule and Escalated Enforcement Actions....................................................……………… 128 P. Procedures for Therapy Treatment With Unsealed Radiopharmaceuticals……. 131 Q. Procedures for Therapy Treatment With Sealed Radiopharmaceuticals………. 139 R. Radiation Safety Terms and Definitions........................................…………….. 143 S. Accepted Half-lives Of Commonly Used Radioisotopes……………………… 150 4 I. Introduction In a comparatively short period of time, the University of Alabama at Birmingham has gained recognition as a center of excellence for teaching, medical services, and research programs. This is a highly commendable achievement and one that could not have been realized without the continued support and dedication of faculty, staff members, and employees. Similar unfailing cooperation and support is necessary for the institution to be equally successful in its development of a comprehensive occupational health and safety program for protection of university personnel, students, and the community. An important part of this program is concerned with safety in research studies and safe disposal of laboratory wastes, including radioisotopes and radiotoxic chemicals. The Department of Public Health for the State of Alabama has granted UAB a broad radioactive materials license and other licenses authorizing the use of radioactive materials. A radioactive materials license of broad scope is issued to institutions that perform a variety of tasks with many different radionuclides. Prior to receiving such a license, an institution must have previously demonstrated that it has the knowledge, resources, and capability for using these materials safely. The UAB Radioisotope and Radiation Safety Committee (RRSC), which is composed of individuals knowledgeable in the various applications of radiation, administers the activities conducted under this license. This committee must approve in advance the manner in which all radioactive materials are licensed, purchased, stored, used, transferred, and disposed. At UAB, there is one other committee which has responsibilities in radiation protection as it applies to human use research with radioactive drugs. This is the Subcommittee for Human Use (SCHU). In addition, the staff of the Radiation Safety Program provides advice and assistance in solving radiological safety problems. It also has the responsibility for evaluating the use of radioisotopes and other radiation sources throughout the University. Any findings and recommendations are discussed with the principal investigator and reported to the appropriate committee. This manual is part of the broad radioactive materials license granted UAB by the State of Alabama, and, as such, cannot be changed without the approval of the UAB RRSC and the Office of Radiation Control, Alabama Department of Public Health. Its purpose is to describe the operation of the radiation safety program and to provide
Recommended publications
  • PART I GENERAL PROVISIONS R12 64E-5.101 Definitions
    64E-5 Florida Administrative Code Index PART I GENERAL PROVISIONS R12 64E-5.101 Definitions ................................................................................................. I-1 64E-5.102 Exemptions ............................................................................................. I-23 64E-5.103 Records ................................................................................................... I-24 64E-5.104 Tests ... ................................................................................................... I-24 64E-5.105 Prohibited Use ........................................................................................ I-24 64E-5.106 Units of Exposure and Dose ................................................................... I-25 64E-5 Florida Administrative Code Index 64E-5 Florida Administrative Code Index PART II LICENSING OF RADIOACTIVE MATERIALS R2 64E-5.201 ...... Licensing of Radioactive Material .............................................................. II-1 64E-5.202 ...... Source Material - Exemptions .................................................................... II-2 R12 64E-5.203 ...... Radioactive Material Other than Source Material - Exemptions ................. II-4 SUBPART A LICENSE TYPES AND FEES R12 64E-5.204 ..... Types of Licenses ..................................................................................... II-13 SUBPART B GENERAL LICENSES 64E-5.205 ..... General Licenses - Source Material .........................................................
    [Show full text]
  • Nrc Regulatory Issue Summary 2005-23 Clarification of the Physical Presence Requirement During Gamma Stereotactic Radiosurgery Treatments
    UNITED STATES NUCLEAR REGULATORY COMMISSION OFFICE OF NUCLEAR MATERIAL SAFETY AND SAFEGUARDS WASHINGTON, D.C. 20555 October 7, 2005 NRC REGULATORY ISSUE SUMMARY 2005-23 CLARIFICATION OF THE PHYSICAL PRESENCE REQUIREMENT DURING GAMMA STEREOTACTIC RADIOSURGERY TREATMENTS ADDRESSEES All gamma stereotactic radiosurgery (GSR) licensees. INTENT The U.S. Nuclear Regulatory Commission (NRC) is issuing this regulatory issue summary (RIS) to clarify the definition of the term “physically present,” as used in 10 CFR 35.615(f)(3). No specific action or written response is required. BACKGROUND In March 2005, during a licensing visit to a GSR facility, the NRC staff observed that the authorized medical physicist (AMP) did not remain physically present throughout one of the GSR treatments, as required by 10 CFR 35.615(f)(3). Instead, during the treatment, the AMP walked to the other end of the GSR suite and entered a treatment planning room located more than 30.5 meters (100 feet) away from the GSR treatment console. While discussing this incident with the licensee, the NRC staff recognized that the licensee was misinterpreting the physical presence requirement for GSR treatments. Based on the licensee’s interpretation of the regulations, the licensee considered any location within the GSR suite, including the treatment planning room, to be within hearing distance of normal voice from the GSR treatment console. The licensee believed that, within the contiguous boundary of its GSR suite, the human voice has sufficient volume, without electronic amplification, to alert the AMP of an emergency at essentially any location within its suite and the AMP could respond in a timely manner.
    [Show full text]
  • Radiosurgery Or Fractionated Stereotactic Radiotherapy Plus Whole-Brain Radioherapy in Brain Oligometastases: a Long-Term Analysis
    ANTICANCER RESEARCH 35: 3055-3060 (2015) Radiosurgery or Fractionated Stereotactic Radiotherapy plus Whole-brain Radioherapy in Brain Oligometastases: A Long-term Analysis MARIO BALDUCCI1, ROSA AUTORINO1, SILVIA CHIESA1, GIANCARLO MATTIUCCI1, ANGELO POMPUCCI2, LUIGI AZARIO3, GIUSEPPE ROBERTO D’AGOSTINO1, MILENA FERRO1, ALBA FIORENTINO1, SERGIO FERSINO1, CIRO MAZZARELLA1, CESARE COLOSIMO4, VINCENZO FRASCINO1, CARMELO ANILE2 and VINCENZO VALENTINI1 Departments of 1Radiation Oncology, 2Neurosurgery, 3Physics and 4Radiology, Catholic University of the Sacred Heart, Rome, Italy Abstract. Aim: To analyze the outcome of patients with number, size, location, the patient’s Karnofsky performance brain oligometastases treated by radiosurgery (SRS) or status (KPS), age, extent of systematic disease and primary fractionated stereotactic radiotherapy (FSRT) after whole- disease status (4, 5). brain radiotherapy (WBRT). Patients and Methods: Overall Patients with one or two brain metastases and with survival (OS) and local control (LC) were evaluated in favorable prognostic features have a relatively favorable patients (patients) with 1-2 brain metastases. Results: Forty- survival; thus, the treatment is frequently more aggressive seven patients were selected. They were submitted to WBRT than for patients with multiple brain metastases (5). (median dose=3,750 cGy) followed by SRS (17 patients; Radiosurgery (SRS) delivered as a single fraction to median dose=1,500 cGy) or FSRT (30 patients; median individual intracranial lesions has been the most common dose=2,000 cGy). Median follow-up was 102 months technique used to dose-escalate on lesions following whole (range=17-151); the median survival was 22 months for the brain radiotherapy (WBRT) and considered as safe SRS group and 16 months for the FSRT group.
    [Show full text]
  • A Roadmap for Replacing High-Risk Radioactive Sources and Materials
    1 Permanent Risk Reduction: A Roadmap for Replacing High-Risk Radioactive Sources and Materials Miles A. Pomper James Martin Center for Nonproliferation Studies The National Academies of Sciences Radioactive Sources: Applications and Alternative Technologies Meeting January 31, 2020 2 Overview • CNS Workshops and Studies • Materials of Security Concern • Uses of Current High-Risk Materials ▫ Medicine ▫ Oil and gas industry • Strategy for Replacing High Activity Sources • Replacement Priority • Encouraging Replacement: Actions • Conclusions 3 CNS Workshops and Studies Since 2008, CNS has led a series of workshops and studies: . Alternatives to High-Risk Radiological Sources: The Case of Cesium Chloride in Blood Irradiation (2014) . Permanent Risk Reduction: A Roadmap for Replacing High-Risk Radioactive Sources and Materials (2015) . Treatment Not Terror: Strategies to Enhance External Beam Cancer Therapy in Developing Countries While Permanently Reducing the Risk of Radiological Terrorism (2016) . Additional material since: for NYC, NTI, and IAEA ICONS, draft language for 2016 NSS 4 Important Current Uses for High-Risk Materials, Existing Alternatives and Challenges, and Suggested Next Steps 5 High-Risk Sources • A task force report by the NRC listed 1. Americium-241 (Am-241) 2. Am-241/Beryllium (Be) 16 radionuclides as those of principal 3. Californium-252 (Cf-252) concern when considering the 4. Cesium-137 (Cs-137) problems they would cause if used in a 5. Cobalt-60 (Co-60) radiological dispersion device (RDD) 6. Curium-244 (Cm-244) • Considered an immediate danger only 7. Gadolinium-153 (Gd-153) when found in large enough amounts 8. Iridium-192 (Ir-192) to threaten life or cause severe 9.
    [Show full text]
  • Linac Based Radiosurgery and Stereotactic Radiotherapy
    Linac Based Radiosurgery and Stereotactic Radiotherapy Thomas Rockwell Mackie Professor Depts. Of Medical Physics, Human Oncology, and Engineering Physics University of Wisconsin Madison WI 53706 [email protected] Conflict of Interest Statement: I have financial interest in TomoTherapy Inc. Acknowledgements Peter Hoban, TomoTherapy Inc. Steve Goetsch, San Diego Gamma Knife Center Fang-Fang Yin, Duke University Chet Ramsey, Thompson Cancer Survival Center Karen Rosser, Royal Marsden Wolfgang Ullrich, BrainLab Inc. Outline Definition of SRS and SRT Stereo Market Indications for SRS/SRT History of Linac-Based SRS/SRT Variety of Systems QA for SRS Localization Imaging Small Field Dosimetry Stereotactic Radiosurgery Usually single fraction delivery » One large dose instead of ~30 fractions as in standard radiotherapy » Usually called SRS Also multiple fraction delivery » Often hypo-fractionated – Small number of fractions (e.g., 5) » Often called stereotactic radiotherapy (SRT) or fractionated stereotactic radiosurgery (FSRS) US Stereotactic Market Dedicated Machines US Stereotactic Market Dedicated Machines In 2003, 83 sites report plans to purchase in next few years 32 units in 2004 85% Linac based 15% Gamma Knife US Stereotactic Market Dedicated Machines Half of all dedicated SRS installations are in last 3 years (to 2003) US Stereotactic Market 100 80 60 40 cumulative number 20 Web Site Claims To 2005 0 1987 1989 1991 1993 1995 1997 GammaKnife CyberKnife 1999 Novalis 2001 2003 2004 2005 Brain Tumors Primary brain tumors » Tumors
    [Show full text]
  • A Framework for Quality Radiation Oncology Care
    Safety is No Accident A FRAMEWORK FOR QUALITY RADIATION ONCOLOGY CARE DEVELOPED AND SPONSORED BY Safety is No Accident A FRAMEWORK FOR QUALITY RADIATION ONCOLOGY CARE DEVELOPED AND SPONSORED BY: American Society for Radiation Oncology (ASTRO) ENDORSED BY: American Association of Medical Dosimetrists (AAMD) American Association of Physicists in Medicine (AAPM) American Board of Radiology (ABR) American Brachytherapy Society (ABS) American College of Radiology (ACR) American Radium Society (ARS) American Society of Radiologic Technologists (ASRT) Society of Chairmen of Academic Radiation Oncology Programs (SCAROP) Society for Radiation Oncology Administrators (SROA) T A R G E T I N G CAN CER CAR E The content in this publication is current as of the publication date. The information and opinions provided in the book are based on current and accessible evidence and consensus in the radiation oncology community. However, no such guide can be all-inclusive, and, especially given the evolving environment in which we practice, the recommendations and information provided in the book are subject to change and are intended to be updated over time. This book is made available to ASTRO and endorsing organization members and to the public for educational and informational purposes only. Any commercial use of this book or any content in this book without the prior written consent of ASTRO is strictly prohibited. The information in the book presents scientific, health and safety information and may, to some extent, reflect ASTRO’s and the endorsing organizations’ understanding of the consensus scientific or medical opinion. ASTRO and the endorsing organizations regard any consideration of the information in the book to be voluntary.
    [Show full text]
  • 1520.Full.Pdf
    ORIGINAL RESEARCH ADULT BRAIN Differentiation between Treatment-Induced Necrosis and Recurrent Tumors in Patients with Metastatic Brain Tumors: Comparison among 11C-Methionine-PET, FDG-PET, MR Permeability Imaging, and MRI-ADC—Preliminary Results X N. Tomura, X M. Kokubun, X T. Saginoya, X Y. Mizuno, and X Y. Kikuchi ABSTRACT BACKGROUND AND PURPOSE: In patients with metastatic brain tumors after gamma knife radiosurgery, the superiority of PET using 11C-methionine for differentiating radiation necrosis and recurrent tumors has been accepted. To evaluate the feasibility of MR permea- bility imaging, it was compared with PET using 11C-methionine, FDG-PET, and DWI for differentiating radiation necrosis from recurrent tumors. MATERIALS AND METHODS: The study analyzed 18 lesions from 15 patients with metastatic brain tumors who underwent gamma knife radiosurgery. Ten lesions were identified as recurrent tumors by an operation. In MR permeability imaging, the transfer constant between intra- and extravascular extracellular spaces (/minute), extravascular extracellular space, the transfer constant from the extravascular extracellular space to plasma (/minute), the initial area under the signal intensity–time curve, contrast-enhancement ratio, bolus arrival time (seconds), maximum slope of increase (millimole/second), and fractional plasma volume were calculated. ADC was also acquired. On both PET using 11C-methionine and FDG-PET, the ratio of the maximum standard uptake value of the lesion divided by the maximum standard uptake value of the symmetric
    [Show full text]
  • 68Ga-DOTATOC PET/CT Follow up After Single Or Hypofractionated Gamma Knife ICON Radiosurgery for Meningioma Patients
    brain sciences Article 68Ga-DOTATOC PET/CT Follow Up after Single or Hypofractionated Gamma Knife ICON Radiosurgery for Meningioma Patients Fabio Barone 1,†, Francesco Inserra 1,†, Gianluca Scalia 2 , Massimo Ippolito 3, Sebastiano Cosentino 3 , Antonio Crea 4,5, Maria Gabriella Sabini 6,7, Lucia Valastro 6,7, Iolanda Valeria Patti 6,7, Stefania Mele 6,7, Grazia Acquaviva 8, Alessandra Tocco 8,9, Maria Tamburo 10, Francesca Graziano 2, Ottavio S. Tomasi 11,12, Rosario Maugeri 13, Gerardo Iacopino 13, Salvatore Cicero 4, Lidia Strigari 14 and Giuseppe Emmanuele Umana 4,* 1 Gamma-Knife Center, Department of Neurosurgery, Cannizzaro Hospital, 95126 Catania, Italy; [email protected] (F.B.); [email protected] (F.I.) 2 Neurosurgery Unit, Highly Specialized Hospital and of National Importance “Garibaldi”, 95122 Catania, Italy; [email protected] (G.S.); [email protected] (F.G.) 3 Department of Advanced Technologies, Nuclear Medicine and PET Cannizzaro Hospital, 95126 Catania, Italy; [email protected] (M.I.); [email protected] (S.C.) 4 Trauma Center, Gamma Knife Center, Department of Neurosurgery, Cannizzaro Hospital, 95126 Catania, Italy; [email protected] (A.C.); [email protected] (S.C.) 5 Neurosurgery Unit, Department of Clinical-Surgical, Diagnostic and Pediatric Sciences, University of Pavia, 27100 Pavia, Italy 6 Medical Physics Unit, Cannizzaro Hospital, 95126 Catania, Italy; [email protected] (M.G.S.); Citation: Barone, F.; Inserra, F.; [email protected] (L.V.); [email protected] (I.V.P.); [email protected] (S.M.) 7 Scalia, G.; Ippolito, M.; Cosentino, S.; INFN-Laboratori Nazionali del Sud, Via S. Sofia 62, 95123 Catania, Italy 8 UOC Radioterapia AOOE Cannizzaro di Catania, 95100 Catania, Italy; [email protected] (G.A.); Crea, A.; Sabini, M.G.; Valastro, L.; [email protected] (A.T.) Patti, I.V.; Mele, S.; et al.
    [Show full text]
  • A Very Effective Treatment for Symptomatic Cerebral Cavernomas PHAM CAM PHUONG 1, NGUYEN DUC LUAN 1, VO THI HUYEN TRANG 1, STEVEN E
    ANTICANCER RESEARCH 37 : 3729-3733 (2017) doi:10.21873/anticanres.11746 Radiosurgery with a Rotating Gamma System: A Very Effective Treatment for Symptomatic Cerebral Cavernomas PHAM CAM PHUONG 1, NGUYEN DUC LUAN 1, VO THI HUYEN TRANG 1, STEVEN E. SCHILD 2, DIRK RADES 3,4 and MAI TRONG KHOA 1,4 1The Nuclear Medicine and Oncology Center, Bach Mai Hospital, Hanoi, Vietnam; 2Department of Radiation Oncology, Mayo Clinic, Scottsdale, AZ, U.S.A.; 3Department of Radiation Oncology, University of Lübeck, Lübeck, Germany; 4Department of Nuclear Medicine, Ha Noi Medical University, Hanoi, Vietnam Abstract. Aim: To evaluate the value of radiosurgery with a At many centers, microsurgical resection is considered rotating gamma-system (RGS) for cerebral cavernomas. standard treatment approach for cerebral cavernomas (2). Patients and Methods: Seventy-nine patients with symptomatic Optimal clinical outcome requires complete resection of cerebral cavernomas underwent RGS radiosurgery at the Bach the cavernoma. Subtotal resection is associated with Mai Hospital, Hanoi, Vietnam. Median dose (single fraction) subsequent episodes of bleeding in approximately 40% of was 20 Gy (range=14-26 Gy). Endpoints included effect on cases (2). Therefore, only very experienced neurosurgeons headache, seizures and tumor size. Results: Of 60 patients with should perform resection of cerebral cavernomas. headache, 17% had complete response, 82% partial response Moreover, neurosurgical resection cannot be recommended and 2% stable disease (best response). Of 39 patients with for lesions in the brainstem or other eloquent areas of the seizures, 31% had complete response, 64% partial response brain, since it may result in significant morbidity. For and 5% stable disease.
    [Show full text]
  • Stereotactic Radiosurgery
    Stereotactic Radiosurgery (SRS) and Stereotactic Body Radiotherapy (SBRT) Stereotactic radiosurgery (SRS) is a non-surgical radiation therapy used to treat functional abnormalities and small tumors of the brain. It can deliver precisely-targeted radiation in fewer high-dose treatments than traditional therapy, which can help preserve healthy tissue. When SRS is used to treat body tumors, it's called stereotactic body radiotherapy (SBRT). SRS and SBRT are usually performed on an outpatient basis. Ask your doctor if you should plan to have someone drive you home afterward and whether you should refrain from eating or drinking or taking medication several hours before treatment. Tell your doctor if there's a possibility you are pregnant or if you're breastfeeding or if you're taking oral medication or insulin to control diabetes. Discuss whether you have an implanted medical device, claustrophobia or allergies to contrast materials. What is stereotactic radiosurgery and how is it used? Stereotactic radiosurgery (SRS) is a highly precise form of radiation therapy initially developed to treat small brain tumors and functional abnormalities of the brain. The principles of cranial SRS, namely high precision radiation where delivery is accurate to within one to two millimeters, are now being applied to the treatment of body tumors with a procedure known as stereotactic body radiotherapy (SBRT). Despite its name, SRS is a non-surgical procedure that delivers precisely-targeted radiation at much higher doses, in only a single or few treatments, as compared to traditional radiation therapy. This treatment is only possible due to the development of highly advanced radiation technologies that permit maximum dose delivery within the target while minimizing dose to the surrounding healthy tissue.
    [Show full text]
  • Medical Sources of Radiation
    Medical Sources of Radiation Professional Training Programs Oak Ridge Associated Universities Objectives To review the most common uses of radiation in medicine. To discuss new uses for radiation in medicine. To review pertinent regulatory issues. 2 Introduction Medical exposure to an average American is about 3 mSv/yrmSv/yr (300 mrem/yr),mrem/yr), or about 48% of the total average exposure of 620 mremmrem.. Medical exposure to radiation is the largest contributor to our annual average exposure from manman--mademade sources. 3 NCRP Report 160 4 Introduction People are intentionally and purposefully irradiated during medical radiological procedures, which is something that is usually avoided in all other applications using radiation. 5 Introduction The goal in medicine is to minimize risk (keep doses low), without compromising the benefit of the procedure (diagnosis or treatment). 6 Introduction Radiation dose to patients is not regulated. Radiation doses per procedure are decreasing (with a few exceptions), but more procedures are being performed. 7 Introduction There are traditionally three branches of medicine that use ionizing radiation. – Diagnostic Imaging – Nuclear medicine – Radiation therapy 8 Diagnostic Imaging Diagnostic X-X-RayRay Fluoroscopy Mammography Bone Densitometry Computed Tomography Special Procedures Cardiac Cath Lab 9 Diagnostic Imaging MRI and ultrasound procedures do not use ionizing radiation, so will not be discussed. 10 Diagnostic Imaging People who have had xx--rayray procedures or CT scans have been exposed to ionizing radiation, but are not radioactive. 11 Diagnostic Imaging The states regulate the users of x-x-rayray equipment, the FDA regulates the manufacture of x-x-rayray equipment. 12 Diagnostic Imaging 13 Diagnostic Imaging 14 Diagnostic Imaging 15 Diagnostic Imaging 16 Nuclear Medicine The patient is purposefully administered radioactive material, and becomes the source of radiation.
    [Show full text]
  • Stereotactic Radiosurgery
    Stereotactic Radiosurgery Clinical Coverage Criteria Overview The adjective “Stereotactic” describes a procedure during which a target lesion is localized relative to a fixed three dimensional reference system, such as a rigid head frame affixed to a patient, fixed bony landmarks, a system of implanted fiducial markers, or other similar system. This type of localization procedure allows physicians to perform image-guided procedures with a high degree of anatomic accuracy and precision. Stereotactic Radiosurgery (SRS) is a distinct discipline that utilizes externally generated ionizing radiation in certain cases to inactivate or eradicate a defined target(s) in the head or spine without the need to make an incision. The target is defined by high-resolution stereotactic imaging. To assure quality of patient care the procedure involves a multidisciplinary team consisting of a neurosurgeon, radiation oncologist, and medical physicist. SRS is typically performed in a single session (multiple fractions may be necessary when lesions are near critical structures), using a rigidly attached stereotactic guiding device, other immobilization technology and/or a stereotactic- guidance system, but can be performed in a limited number of sessions, up to a maximum of five. Technologies that are used to perform SRS include linear accelerators, particle beam accelerators, and multisource Cobalt 60 units. In order to enhance precision, various devices may incorporate robotics and real time imaging. Stereotactic body radiation therapy (SBRT) couples this anatomic accuracy and reproducibility with very high doses of highly precise, externally generated, ionizing radiation, thereby maximizing the ablative effect on the target(s) while minimizing collateral damage to adjacent tissues. SBRT is used to treat extra-cranial sites as opposed to SRS which is used to treat intra- cranial and spinal targets, and may be delivered in one to five sessions (fractions).
    [Show full text]